Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion

The study is a randomized, open, prospective phase II study. The aim of the study is to evaluate the safety and feasibility of a hypofractionated, accelerated radiation approach based on the incidence of grade 3-5 NCI Common Terminology Criteria for Adverse Events (NCI-CTC-AE ) toxicity and / or termination of the planned therapy for any reason with neoadjuvant radiation with active beam guidance of the retroperitoneal Sarcomas using protons or carbon ions before a subsequent tumor resection.

Trial Details

NCT ID
NCT04219202
Phase
NA
Sponsor
University Hospital Heidelberg
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Proton radiation
  • Carbon Ion radiation
Locations (sample)
  • Heidelberg, Germany|49.40768,8.69079

Key Eligibility Criteria

  • Histologically confirmed retroperitoneal soft-tissue sarcoma which is resectable or marginally resectable
  • Karnofsky index of ≥ 70%
  • Age from 18 years
  • Completed patient information and written consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →